Global Immuno-Oncology Therapy Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Therapy Type;
Monoclonal Antibodies, Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, and Others.By Therapeutic Area;
Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Melanoma, Blood Cancer, and Others.By End-User;
Hospitals, Clinics, Ambulatory Surgical Centers (ASC’s), and Cancer Research Institutes.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).Introduction
Global Immuno-Oncology Therapy Market (USD Million), 2021 - 2031
In the year 2024, the Global Immuno-Oncology Therapy Market was valued at USD 108,788.19 million. The size of this market is expected to increase to USD 289,378.74 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 15.0%.
The Global Immuno-Oncology Therapy Market has experienced significant growth and innovation in recent years due to substantial advancements in cancer immunotherapy. Immuno-oncology therapies leverage the body's immune system to identify and combat cancer cells, representing a promising approach for treating various cancer types. This market encompasses a diverse array of treatments, including immune checkpoint inhibitors, CAR-T cell therapies, cancer vaccines, and cytokine-based therapies, all designed to target different aspects of the immune response against cancer.
The rising global incidence of cancer, coupled with a deeper understanding of the immune system's role in cancer development and progression, has been a driving force behind the expansion of the immuno-oncology therapy market. Immunotherapy has emerged as a transformative area within oncology, with therapies demonstrating impressive efficacy and durable responses in specific cancer types. Key factors propelling market growth include ongoing research and development efforts focused on refining existing therapies and exploring novel approaches to enhance immune-mediated cancer treatment.
Immuno-oncology therapies have revolutionized cancer treatment by offering new options for patients who may not respond to conventional treatments like chemotherapy or radiation. The market landscape is dynamic, characterized by innovative biologics and precision medicine approaches, underpinned by collaborations between pharmaceutical firms, academic institutions, and research entities. As the immuno-oncology therapy market continues to evolve with ongoing clinical trials and regulatory approvals, it holds immense potential for advancing patient outcomes and reshaping the landscape of cancer care globally.
Global Immuno-Oncology Therapy Market Recent Developments
- In October 2023, Pfizer launched the MEKTOVI (binimetinib) + BRAFTOVI (encorafenib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test has received approval from U.S. Food and Drug Administration (FDA)
- In October 2023, Merck's anti-PD-1 therapy KEYTRUDA was approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable non-small cell lung cancer (NSCLC) as neoadjuvant treatment and adjuvant treatment following surgery
Segment Analysis
The global Immuno-Oncology Therapy market features a wide array of therapeutic approaches aimed at leveraging the body's immune system to combat cancer. This includes Monoclonal Antibodies, which target specific cancer cells or immune checkpoints to enhance immune response; Immune Checkpoint Inhibitors, which release the brakes on immune cells to attack cancer; Immune System Modulators, which stimulate or suppress immune responses to target cancer cells; and Cancer Vaccines, designed to boost the immune system against cancer-specific antigens. These therapies represent cutting-edge strategies in cancer treatment, offering personalized and targeted options for patients.
In terms of therapeutic areas, Immuno-Oncology therapies are applied across various types of cancer, including Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Melanoma, Blood Cancer, and others. Each of these areas presents unique challenges and opportunities for immuno-oncology interventions. For instance, Lung Cancer has been a major focus due to its prevalence and the potential of immunotherapies like checkpoint inhibitors, while melanoma has seen significant advancements with targeted immunotherapies yielding promising outcomes.
End-users of Immuno-Oncology therapies include hospitals, clinics, ambulatory surgical centers (ASCs), and cancer research institutes. Hospitals and clinics are pivotal settings for delivering these therapies, providing comprehensive cancer care and management. Ambulatory surgical centers cater to outpatient procedures, offering convenient access to specific immuno-oncology treatments. Cancer research institutes play a crucial role in advancing immuno-oncology through research, clinical trials, and educational initiatives aimed at improving treatment outcomes and patient care.
Geographically, the Immuno-Oncology Therapy market spans North America, Europe, Asia Pacific, Middle East and Africa, and Latin America. North America and Europe lead in market share and research innovation, benefiting from established healthcare infrastructures and high adoption rates of immuno-oncology treatments. The Asia Pacific region is experiencing rapid growth due to increasing cancer prevalence and improving access to advanced therapies. Meanwhile, Middle East and Africa, as well as Latin America, are emerging markets showing rising investments in healthcare and a growing focus on cancer care, thereby driving demand for immuno-oncology therapies. Overall, the global landscape of immuno-oncology therapy reflects a dynamic field with substantial potential for further advancements in cancer treatment.
Global Immuno-Oncology Therapy Segment Analysis
In this report, the global immuno-oncology therapy market has been segmented by therapy Type, Therapeutic area, End-User and Geography.
Global Immuno-Oncology Therapy Market, Segmentation by Therapy Type
The Global Immuno-Oncology Therapy Market has been segmented by Therapy Type into Monoclonal Antibodies, Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines and Others.
Monoclonal Antibodies target cancer cells by either marking them for immune system destruction or delivering toxic substances directly to cancerous cells. Immune Checkpoint Inhibitors block pathways used by cancer cells to evade immune detection, thus enhancing the immune response against tumors, particularly in advanced or metastatic cancers.
Immune System Modulators are pivotal in regulating and enhancing immune responses against cancer. They stimulate immune cells to recognize and attack cancer cells more effectively, boosting overall anti-tumor immunity. Cancer Vaccines train the immune system to identify and combat cancer cells bearing specific antigens, offering both preventive and therapeutic benefits while sparing normal tissues. Additionally, the immuno-oncology field is advancing with novel approaches such as adoptive cell therapies, oncolytic viruses, and targeted immunomodulators, each tailored to bolster immune responses against cancer in unique ways.
The immuno-oncology therapy market remains dynamic, with continuous research and development efforts aimed at expanding treatment options, enhancing efficacy, and managing potential side effects. Progress in understanding the intricate interplay between cancer cells and the immune system fuels ongoing innovation in immuno-oncology. These advancements provide renewed hope for patients with historically challenging cancers, fostering a path towards more personalized and effective cancer therapies that capitalize on the body's natural defenses against malignancies.
Global Immuno-Oncology Therapy Market, Segmentation by Therapeutic Area
The Global Immuno-Oncology Therapy Market has been segmented by Therapeutic Area into Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Melanoma, Blood Cancer and Others.
In lung cancer, notable progress has been made with immune checkpoint inhibitors like pembrolizumab and nivolumab, demonstrating efficacy in specific subsets of non-small cell lung cancer (NSCLC) patients. Colorectal cancer has also witnessed advancements, with immune checkpoint inhibitors and combination therapies offering new options for patients who have exhausted standard treatment options.
Breast cancer, a prevalent cancer type worldwide, is a significant focus of immuno-oncology research. While immunotherapy has not yet become standard across all breast cancer subtypes, ongoing studies aim to identify biomarkers and develop targeted immunotherapies tailored to specific patient populations. In prostate cancer, particularly in advanced and metastatic cases, there is emerging interest in immune checkpoint inhibitors and vaccine-based therapies as potential treatment avenues.
Melanoma, known for its immunogenic nature, has been a cornerstone indication for immuno-oncology therapies. Drugs like ipilimumab and pembrolizumab have shown durable responses and improved survival outcomes in metastatic melanoma patients. Additionally, blood cancers such as lymphoma, leukemia, and multiple myeloma have seen significant strides with CAR-T cell therapies and other immunotherapeutic strategies, leading to FDA approvals and expanded treatment options for these hematologic malignancies.
Beyond these focal areas, immuno-oncology research is expanding into diverse cancer types including ovarian cancer, head and neck cancers, renal cell carcinoma, and pancreatic cancer, among others. The global landscape of immuno-oncology continues to evolve rapidly, driven by ongoing clinical investigations, biomarker discoveries, and collaborative efforts among researchers, clinicians, and pharmaceutical entities. As our understanding of the intricate relationship between the immune system and cancer deepens, the potential for innovative and personalized immuno-oncology treatments to benefit patients across various cancer types remains a promising frontier in modern cancer therapy.
Global Immuno-Oncology Therapy Market, Segmentation by End-User
The Global Immuno-Oncology Therapy Market has been segmented by End-User into Hospitals, Clinics, Ambulatory Surgical Centers (ASCs) and Cancer Research Institutes.
Hospitals are pivotal in delivering immuno-oncology therapies, offering comprehensive cancer care ranging from diagnosis to treatment and follow-up. With specialized oncology departments and multidisciplinary teams, hospitals are equipped to manage complex cases requiring advanced immuno-oncology interventions. Clinics also play a significant role, providing outpatient services for cancer diagnosis, treatment, and supportive care, ensuring convenient access to immuno-oncology therapies for patients outside of hospital settings.
Ambulatory Surgical Centers (ASCs) are emerging as important contributors to the immuno-oncology market, offering specialized procedures and treatments on an outpatient basis. These centers provide cost-effective and convenient alternatives to traditional hospital-based care for certain immuno-oncology procedures such as infusions, biopsies, and minor surgeries. ASCs prioritize personalized care in comfortable settings, enhancing patient experience and optimizing resource utilization. Additionally, cancer research institutes are critical in advancing immuno-oncology therapies through translational research, clinical trials, and innovation. They focus on developing novel therapies, understanding treatment resistance mechanisms, and exploring personalized approaches to cancer immunotherapy.
The distribution and utilization of immuno-oncology therapies among different end-users are influenced by factors like access to specialized expertise, infrastructure, and reimbursement policies. Hospitals and clinics remain primary settings for immuno-oncology treatment delivery due to their comprehensive capabilities and patient-centric care models. ASCs are increasingly adopting immuno-oncology services to meet the rising demand for outpatient cancer care and reduce hospitalization costs. Cancer research institutes serve as hubs for cutting-edge research and development in immuno-oncology, fostering collaborations among academia, industry, and healthcare providers to translate scientific discoveries into clinical applications.
The global Immuno-Oncology Therapy market relies on a network of diverse end-users, including hospitals, clinics, ASCs, and cancer research institutes, to deliver innovative therapies and advance cancer care. Each end-user plays a unique role in the continuum of cancer treatment, contributing to diagnosis, therapeutic intervention, and research. Collaborative efforts among these stakeholders drive progress in immuno-oncology, offering renewed hope and improved outcomes for cancer patients worldwide.
Global Immuno-Oncology Therapy Market, Segmentation by Geography
In this report, the Global Immuno-Oncology Therapy Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Immuno-Oncology Therapy Market Share (%), by Geographical Region, 2024
The Global Immuno-Oncology Therapy Market exhibits geographical diversity, with different regions making unique contributions to the development and adoption of these innovative cancer treatments. North America emerges as a primary market for immuno-oncology therapies, driven by robust research and development activities, well-established healthcare infrastructure, and favorable regulatory frameworks. The United States leads in market size and innovation, with numerous clinical trials and approvals for various immuno-oncology drugs across diverse cancer types.
In Europe, substantial investment and interest in immuno-oncology are observed, with countries like Germany, the UK, and France playing pivotal roles in research and clinical advancements. European regulatory agencies have been proactive in evaluating and approving new immuno-oncology treatments, contributing to the region's expanding market landscape. Adoption rates of these therapies vary across European countries due to differences in reimbursement policies and healthcare system structures.
The Asia Pacific region is witnessing rapid growth in the immuno-oncology therapy market, driven by increasing cancer incidence, rising healthcare expenditure, and improved access to advanced treatments. Countries such as China, Japan, and South Korea are leading in immuno-oncology research and development, with a surge in clinical trials and collaborations with global pharmaceutical companies. Enhancements in regulatory frameworks and initiatives to promote innovation further propel market expansion in this region.
Latin America, the Middle East, and Africa show a growing interest in immuno-oncology therapies, although market penetration and access to advanced treatments vary across these regions. Challenges related to healthcare infrastructure, regulatory processes, and affordability present barriers to widespread adoption in some areas. Nevertheless, efforts are underway to strengthen healthcare systems, raise awareness about immuno-oncology, and foster international collaborations to improve patient access to cutting-edge cancer treatments. As the global immuno-oncology therapy market evolves, addressing geographic disparities in adoption and access remains critical for advancing cancer care on a global scale.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Immuno-Oncology Therapy Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers:
- Increasing Incidence of Cancer
- Advancements in Biotechnology and Immunology
-
Increasing Investments in Research and Development: Increasing investments in research and development within the field of immuno-oncology are playing a pivotal role in propelling market growth. Pharmaceutical companies, biotechnology firms, and research institutions are dedicating substantial resources to advance immuno-oncology therapies. These investments support the exploration of novel treatment approaches, including immune checkpoint inhibitors, CAR-T cell therapies, and therapeutic vaccines. By funding innovative research projects and clinical trials, stakeholders in the industry aim to expand the repertoire of effective cancer treatments and address unmet medical needs.
Collaborations and partnerships between industry players and academic institutions are fostering accelerated progress in immuno-oncology research. These collaborations facilitate knowledge exchange, access to cutting-edge technologies, and shared expertise, ultimately translating scientific discoveries into tangible clinical applications. By leveraging the strengths of diverse stakeholders, such as expertise in molecular biology, immunology, and clinical trial design, collaborative efforts drive the development of clinically viable immuno-oncology therapies. This collaborative approach also enhances the efficiency of research and development processes, enabling faster translation of promising discoveries into therapeutic interventions.
The impact of increased research and development investments extends beyond basic science to the expansion of treatment indications and the optimization of patient outcomes. As new insights into the complex interactions between the immune system and cancer cells emerge, the landscape of immuno-oncology continues to evolve. Targeted investments support the identification of biomarkers for patient stratification, the development of personalized treatment regimens, and the exploration of combination therapies. Ultimately, the collective efforts of stakeholders in immuno-oncology research and development contribute to advancing cancer care, offering hope to patients and driving the growth of the global immuno-oncology therapy market.
Restraints:
- High Cost of Therapy
- Immune-related Adverse Events
-
Regulatory Challenges: Navigating regulatory challenges is a critical aspect of bringing immuno-oncology therapies to market. Stringent regulatory requirements dictate the approval and commercialization processes, necessitating extensive clinical trial data to demonstrate the safety and efficacy of these therapies. Meeting these standards requires significant investments of time, resources, and expertise from pharmaceutical companies and biotechnology firms. The rigorous evaluation process aims to ensure patient safety and uphold quality standards, but it can also pose barriers to timely market access for innovative immuno-oncology treatments.
The complexity of regulatory landscapes across different regions and countries adds another layer of challenge for market players in the immuno-oncology sector. Each regulatory authority may have distinct requirements, timelines, and documentation standards for drug approval. This diversity necessitates tailored strategies and meticulous planning to navigate the intricacies of multiple regulatory environments effectively. Delays in obtaining regulatory approvals can prolong the time-to-market for immuno-oncology therapies, impacting patient access and market competitiveness.
Despite the challenges posed by regulatory requirements, adherence to rigorous standards is essential for ensuring patient safety and maintaining public trust in immuno-oncology therapies. Pharmaceutical companies and biotechnology firms must engage in proactive dialogue with regulatory agencies to streamline approval processes and harmonize regulatory pathways across regions where possible. Collaboration between industry stakeholders and regulatory authorities is crucial for addressing regulatory challenges, fostering innovation, and ultimately facilitating timely access to transformative immuno-oncology treatments for cancer patients worldwide.
Opportunities:
- Expansion into Combination Therapies
- Focus on Personalized Medicine
-
Emerging Markets and Global Expansion: Emerging markets hold significant potential for the expansion of immuno-oncology therapies, driven by rising cancer rates, improving healthcare infrastructure, and growing investments in healthcare. These markets, found predominantly in emerging economies, offer untapped opportunities for pharmaceutical companies and biotechnology firms to introduce innovative immuno-oncology treatments. As cancer incidence increases in these regions, there is a growing demand for advanced therapies that can improve patient outcomes. Concurrently, investments in healthcare infrastructure enhance access to specialized cancer care, creating a favorable environment for market expansion.
Strategic partnerships and market access initiatives play a crucial role in facilitating entry into emerging markets for immuno-oncology therapies. Collaborations between industry players, local healthcare providers, and government agencies enable tailored approaches to address specific market needs and challenges. By forming strategic alliances, companies can leverage local expertise, navigate regulatory landscapes, and establish distribution channels effectively. Market access initiatives focus on optimizing affordability and availability of immuno-oncology treatments, ensuring broader patient access in emerging economies.
Regulatory harmonization efforts are essential for facilitating global expansion of immuno-oncology therapies into emerging markets. Standardizing regulatory processes across different regions promotes efficiency and predictability in drug approval timelines. Pharmaceutical companies benefit from streamlined pathways that reduce administrative burden and accelerate market entry. Regulatory harmonization enhances patient safety by ensuring adherence to consistent quality and efficacy standards. Overall, leveraging strategic partnerships, market access initiatives, and regulatory harmonization efforts is key to expanding the reach of immuno-oncology therapies and addressing unmet medical needs in emerging markets worldwide.
Competitive Landscape Analysis
Key players in Global Immuno-Oncology Therapy Market include:
- Amgen, Inc.
- AstraZeneca Plc.
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- F.Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc.
- Janssen Biotech
- Merck and Co.
- Novartis AG
- Pfizer, Inc.
- Sanofi
- Spectrum Pharmaceuticals, Inc.
- Takeda Pharmaceuticals
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Therapy Type
- Market Snapshot, By Therapeutic Area
- Market Snapshot, By End-User
- Market Snapshot, By Region
- Global Immuno-Oncology Therapy Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers:
- Increasing Incidence of Cancer
- Advancements in Biotechnology and Immunology
- Increasing Investments in Research and Development
- Restraints:
- High Cost of Therapy
- Immune-related Adverse Events
- Regulatory Challenges
- Opportunities:
- Expansion into Combination Therapies
- Focus on Personalized Medicine
- Emerging Markets and Global Expansion
- Drivers:
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Immuno-Oncology Therapy Market, By Therapy Type, 2021 - 2031 (USD Million)
- Monoclonal Antibodies
- Immune Checkpoint Inhibitors
- Immune System Modulators
- Cancer Vaccines
- Others
- Global Immuno-Oncology Therapy Market, By Therapeutic Area, 2021 - 2031 (USD Million)
- Lung Cancer
- Colorectal Cancer
- Breast Cancer
- Prostate Cancer
- Melanoma
- Blood Cancer
- Others
- Global Immuno-Oncology Therapy Market, By End-User, 2021 - 2031 (USD Million)
- Hospitals
- Clinics
- Ambulatory Surgical Centers (ASC’s)
- Cancer Research Institutes
- Global Immuno-Oncology Therapy Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Immuno-Oncology Therapy Market, By Therapy Type, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Amgen, Inc.
- AstraZeneca Plc.
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- F.Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc.
- Janssen Biotech
- Merck and Co.
- Novartis AG
- Pfizer, Inc.
- Sanofi
- Spectrum Pharmaceuticals, Inc.
- Takeda Pharmaceuticals
- Company Profiles
- Analyst Views
- Future Outlook of the Market